Literature DB >> 10219645

Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants.

N Linder1, Y Karetnyi, Y Gidony, R Dagan, G Ohel, E Levin, E Mendelson, A Barzilai.   

Abstract

In a previous study we have shown that transplacental transfer of hepatitis A antibodies to preterm infants does not differ from that observed in full-term infants. This follow-up study was designed to investigate the decline of hepatitis A virus (HAV) antibodies during the first 7 months of life in full-term and preterm infants, in an endemic region for hepatitis A. Two hundred and fifty newborn infants--147 full-term and 103 preterm infants--were enrolled. Blood samples from the infants were taken at birth, and at 3 and 7 months of age. Anti-HAV titers were determined by ELISA. A concentration of > or = 1:20 mlU/ml was considered protective. Protective hepatitis A antibodies were present at birth in 48.3% of all full-term and 49.5% of all premature infants. By the age of 7 months only 13% of full-term and 21.7% of preterm infants still had protective titers. For the seropositive full-term infants the geometric mean titers (GMT) were 15,698, 6,107 and 345 at birth, 3 months and 7 months, respectively, and for preterm infants, 10,378, 2,307 and 225 at birth, 3 months and 7 months, respectively. Significant differences in GMT between preterm and full-term infants were found at birth and at 3 months of age (P < 0.05). In a region endemic for hepatitis A, low levels of anti-HAV at 7 months of age may justify trials on infant vaccination since this is the most effective way to eliminate hepatitis A from circulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219645     DOI: 10.1007/bf02560513

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  Preliminary serologic studies of antibody to hepatitis A virus in populations in the United States.

Authors:  J E Maynard; D W Bradley; C L Hornbeck; R M Fields; I L Doto; F B Hollinger
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

2.  Prevalence of antibodies to hepatitis A virus among urban children aged 0-7 years in Yugoslavia.

Authors:  V Burek; A Baće; M Kacić; D Belosević; B Mravunac
Journal:  J Infect       Date:  1985-01       Impact factor: 6.072

3.  The postnatal decline in antibody to hepatitis A virus.

Authors:  M C Willcox; C Andersson; I Olsson
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

4.  Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions.

Authors:  M S Green; C Block; P E Slater
Journal:  Rev Infect Dis       Date:  1989 May-Jun

5.  Prevalence of antibodies against hepatitis A virus among new immigrants in Israel.

Authors:  Y V Karetnyi; E Mendelson; E Shlyakhov; E Rubinstein; N Golubev; R Levin; M Sandler; M Schreiber; U Rubinstein; I Shif
Journal:  J Med Virol       Date:  1995-05       Impact factor: 2.327

6.  Inactivated virosome hepatitis A vaccine.

Authors:  L Loutan; P Bovier; B Althaus; R Glück
Journal:  Lancet       Date:  1994-02-05       Impact factor: 79.321

7.  Serum immunoglobulin levels in premature and full-term infants.

Authors:  H E Evans; S O Akpata; L Glass
Journal:  Am J Clin Pathol       Date:  1971-09       Impact factor: 2.493

8.  Hepatitis A antibodies: prevalence and persistence in a group of Mexican children.

Authors:  J Ruiz-Gomez; M E Bustamante-Calvillo
Journal:  Am J Epidemiol       Date:  1985-01       Impact factor: 4.897

9.  Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Authors: 
Journal:  MMWR Recomm Rep       Date:  1996-12-27

10.  Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.

Authors:  M S Green; D Cohen; Y Lerman; M Sjogren; L N Binn; S Zur; R Slepon; G Robin; C Hoke; W Bancroft
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

View more
  2 in total

1.  Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach.

Authors:  Wail A Hayajneh; Vincent J Daniels; Cerise K James; Muhammet Nabi Kanıbir; Matthew Pilsbury; Morgan Marks; Michelle G Goveia; Elamin H Elbasha; Erik Dasbach; Camilo J Acosta
Journal:  BMC Infect Dis       Date:  2018-03-07       Impact factor: 3.090

2.  The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy.

Authors:  Shiyi Chen; Yuping Zhao; Zhiyao Yang; Ying Li; Hongyuan Shi; Ting Zhao; Xiaolei Yang; Jing Li; Guoliang Li; Jianfeng Wang; Zhifang Ying; Jingsi Yang
Journal:  Hum Vaccin Immunother       Date:  2022-01-19       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.